Latest Breaking News On - Head of corporate communications investor relations - Page 9 : comparemela.com

Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis

Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalBasel stadtUnited statesNils schrMarc engelhardtStevens johnsonJournal of the pediatric infectious diseases societyAstellas pharma us incEuropean commissionEuropean medicines agencyBasilea pharmaceutica ltdHead of corporate communications investor relationsSwiss exchangeDrug administrationEuropean unionPharmaceutica ltd

NLS Pharmaceutics : UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS - Form 6-K -December 06, 2023 at 04:49 pm EST

UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page .

United statesSilvia panigoneSubhasis royCarlos camozziMarianne lambertsonFelix grisardEric konofalGeorge apostolMaria nayvaltRonald hafnerUs eric konofalAlexander zwyerThomas curatoloAstrid sommerCompany board of directorsCompany annual report on form

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalBasel stadtUnited statesAsia pacificDavid veitchIsavuconazole cresembaNils schrPfizer incBasilea pharmaceutica ltdHead of corporate communications investor relationsEuropean unionSwiss exchangePharmaceutica ltdChief executive officerCorporate communicationsPublic assessment report

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting.

Basel stadtSwitzerland generalUnited statesDavid veitchCresemba zevteraNils schrDrug administrationAmplyx pharmaceuticals incSwiss exchangeHead of corporate communications investor relationsAmerican thoracic societyBasilea pharmaceutica international ltdBasilea pharmaceutica ltdPfizer incPharmaceutica ltdAmplyx pharmaceuticals

Basilea announces acquisition of fosmanogepix, a

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a.

Basel stadtUnited statesSwitzerland generalNils schrCresemba zevteraDavid veitchDrug administrationSwiss exchangeAmplyx pharmaceuticals incAmerican thoracic societyHead of corporate communications investor relationsPfizer incBasilea pharmaceutica ltdBasilea pharmaceutica international ltdPharmaceutica ltdAmplyx pharmaceuticals